The EDC is live today — see what ships now
All studies
NCT07294170From ClinicalTrials.govRecruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  • Myasthenia Gravis
  • MG
  • gMG
  • Generalized Myasthenia Gravis
  • Generalized Myasthenia Gravis (gMG)
  • AChR-Ab Seropositive Generalized Myasthenia Gravis

At a glance

Phase
Phase not stated
Study type
Observational
Sponsor
argenx
Enrolment target
70
Started
19 December 2025
Main results due
7 March 2028
Study sites
36
Registry updated
24 September 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Is at least 18 years of age and the local legal age of consent for clinical studies
* Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment
* If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening

Exclusion Criteria:

* Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk
* Is MGFA (Myasthenia Gravis Foundation of America) Class V

What this study is about

In the sponsor’s own words, from the registry.

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Study sites(36)

  • Profound Research LLC - Carlsbad

    Carlsbad, California, United States

    Recruiting

  • Visionary Investigators Network

    Miami, Florida, United States

    Recruiting

  • Visionary Investigators Network

    Miami, Florida, United States

    Recruiting

  • University of South Florida

    Tampa, Florida, United States

    Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Recruiting

  • Henry Ford Health System

    Detroit, Michigan, United States

    Recruiting

  • Profound Research LLC at Las Vegas Neurology Center

    Las Vegas, Nevada, United States

    Recruiting

  • Dent Neurologic Institute - Amherst

    Amherst, New York, United States

    Recruiting

  • University of North Carolina at Chapel Hill-170 Manning Dr.

    Chapel Hill, North Carolina, United States

    Recruiting

  • Duke Early Phase Clinical Research Unit - PPDS

    Durham, North Carolina, United States

    Recruiting

  • University of Cincinnati Medical Center - Goodman St

    Cincinnati, Ohio, United States

    Recruiting

  • Ohio State Martha Morehouse Outpatient Care

    Columbus, Ohio, United States

    Recruiting

  • Erlanger Health System

    Chattanooga, Tennessee, United States

    Recruiting

  • National Neuromuscular Research Institute

    Austin, Texas, United States

    Recruiting

  • University of Texas- San Antonio - Health Science Center - PPDS

    San Antonio, Texas, United States

    Recruiting

  • UZ Leuven - PPDS

    Leuven, Belgium

    Recruiting

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

    Recruiting

  • Universitätsmedizin Göttingen

    Göttingen, Germany

    Recruiting

  • Universitätsklinikum Würzburg

    Würzburg, Germany

    Recruiting

  • Eginitio Hospital

    Athens, Greece

    Recruiting

  • AHEPA University General Hospital of Thessaloniki

    Thessaloniki, Greece

    Recruiting

  • ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII

    Bergamo, Lombardy, Italy

    Recruiting

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Lombardy, Italy

    Recruiting

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

    Recruiting

  • AORN Antonio Cardarelli

    Naples, Italy

    Recruiting

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan

    Recruiting

  • St. Marianna University Hospital

    Kawasaki-Shi, Kanagawa, Japan

    Recruiting

  • National Hospital Organization Sendai Medical Center

    Sendai, Miyagi, Japan

    Recruiting

  • General Hanamaki Hospital - Kajomachi

    Hanamaki, Japan

    Recruiting

  • IUHW Narita Hospital

    Narita, Japan

    Recruiting

  • MICS Centrum Medyczne Bydgoszcz

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

    Recruiting

  • Krakowska Akademia Neurologii Sp. z o.o.

    Krakow, Lesser Poland Voivodeship, Poland

    Recruiting

  • Centrum Medyczne Neurologia Slaska

    Katowice, Silesian Voivodeship, Poland

    Recruiting

  • Warszawski Uniwersytet Medyczny

    Warsaw, Poland

    Recruiting

  • Hospital Regional Universitario de Malaga - Hospital General

    Málaga, Malaga, Spain

    Recruiting

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, Spain

    Recruiting

Showing 36 of 36 sites. 36 of the 36 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07294170. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens i | Trialion